UCB announces new formulation of Keppra XR

ATLANTA UCB has released a new formulation of an epilepsy drug, the Belgian drug maker announced Friday.

The company released a 750 mg formulation of the drug Keppra XR (levetiracetam) extended-release tablets, saying it would allow doctors to simplify patients’ treatment plans by decreasing the number of tablets they take every day.

Studies published in the journals Epilepsy & Behavior and Neurology have suggested that patients are more likely to adhere to medication regimens when they take one pill daily.

Keppra XR is also available in a 500 mg formulation.